1. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis;Adams,2018
2. Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial;Adams,2023
3. Oxidative stress and inflammation in the evolution of heart failure: from pathophysiology to therapeutic strategies;Aimo,2020
4. Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta‐analysis of screening studies;Aimo,2022
5. Interleukin-6 in patients with heart failure and preserved ejection fraction;Alogna,2023